Since HDAC inhibitors have been found to induce neuronal-like differentiation in glioma cells [9,10], and there are currently no reports on such effects related to the drug targets of parthenolide except HDAC1, we focused our attention on HDAC1. Here, HDAC9 is linked to central nervous system cancer.